3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
1
Endocrine
1
CNS
1
Conditions
Carcinoma, Renal Cell
12
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
von Hippel-Lindau Disease
2
Pheochromocytoma
1
Paraganglioma
1
Kidney Neoplasms
1
Carcinoma
1
Breast Neoplasms
1
Adenoma, Islet Cell
1
Interventions
belzutifan
2
palbociclib
1
lenvatinib
1
cabozantinib
1
Nivolumab
1
Everolimus
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
von Hippel-Lindau Disease
×
belzutifan
×
30 days
×
Clear all
NCT07405164
2026-05-29
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3
Recruiting
450 enrolled
NCT04924075
2026-05-28
MK-6482-015
Merck Sharp & Dohme LLC
Phase 2
Recruiting
322 enrolled
1 FDA